Nearly 12 million bottles of Rohto eye drops have been recalled over concerns they may not be sterile, according to a Food and Drug Administration (FDA) enforcement report.

The voluntary recall was issued by Vietnam-based Rohto-Mentholatum and includes eye drops marketed to relieve redness, dryness and eye strain.

According to the FDA, the recall affects 11,960,623 cartons of Rohto Cooling Eye Drops distributed nationwide.

The FDA said the products were recalled because of a “lack of assurance of sterility,” meaning the eye drops cannot be guaranteed to be free of potentially harmful microorganisms.

MILLIONS OF PRESCRIPTION EYE DROPS RECALLED NATIONWIDE OVER CONTAMINATION CONCERNS

Federal regulators classified the action as a Class II recall, meaning use of the products could cause temporary or medically reversible health effects, but serious adverse health consequences are unlikely.

The recall covers eight Rohto Cooling Eye Drops products — including ALL-IN-ONE, Max Strength, Optic Glow, Digi Eye, Dry Aid and Cool Relief — in single and twin-pack configurations.

Affected products carry expiration dates ranging from July 2025 through February 2029. Consumers should compare the lot number and expiration date on their packaging with the manufacturer’s recall notice or the FDA’s website to determine whether their product is included.

MORE THAN 120K REFRIGERATORS RECALLED AFTER 34 FIRES AND ONE REPORTED DEATH

The eye drops were manufactured by Rohto-Mentholatum in Vietnam and distributed by The Mentholatum Company, based in Orchard Park, New York.

Consumers whose products are included in the recall should stop using them immediately and either dispose of them or return them to the place of purchase for a full refund.

The recall comes after the FDA recently classified the recall of more than 2.5 million bottles of a prescription steroid eye medication as a Class II action because of concerns about foreign material found in certain lots.

CLICK HERE TO GET FOX BUSINESS ON THE GO

Lupin Pharmaceuticals Inc. voluntarily recalled 2,530,182 bottles of prednisolone acetate ophthalmic suspension USP, 1%, after the presence of a foreign substance was identified, according to an FDA enforcement report.

Last month, the FDA also announced the recall of certain lots of generic cetirizine hydrochloride tablets, commonly sold as generic versions of Zyrtec, over concerns they may have been cross-contaminated with another medication that could trigger potentially life-threatening reactions.

FOX Business’ Brittany Miller and Bonny Chu contributed to this report.

The artificial intelligence (AI) boom is entering a more unforgiving phase as investors begin questioning whether Big Tech’s unprecedented spending will generate adequate returns or merely consume billions of dollars in cash. Jefferies’ Head of Global Equity Strategy Chris Wood said markets are now responding negatively to increases in capital expenditure, a warning signal for hyperscalers that have committed vast sums to AI infrastructure. While announced results have yet to indicate an outright decline in spending, deteriorating free cash flow and sharp share price reactions suggest investors are no longer prepared to reward capex at any cost.

Wood’s long-standing view is that the “hyperscalers will end up blowing a lot of money on their capex binge” and that AI could resemble the airline industry more than the winner-takes-all economics of the internet era.

The warning follows sharp investor reactions to earnings and spending plans from some of the world’s biggest technology companies.

Alphabet was punished after turning free cash flow negative in the second quarter of 2026 for the first time since its IPO in 2004, according to Wood’s GREED & fear report.

Meta shares fell as its free cash flow plunged 91% to $784 million in the second quarter, from $8.5 billion in the same period last year. The company also raised the lower end of its 2026 capex guidance, taking the range to $130-$145 billion from $125-$145 billion.

Microsoft provided the contrast. Its shares gained 8% after it maintained calendar year 2026 capex guidance at approximately $175 billion. That figure was adjusted from an earlier $190 billion estimate because of accounting changes related to the useful life of assets and the movement of finance leases to operating leases, which are not included in capex.
Also Read | Chris Wood’s big warning: The specific risk that will finally trigger the end of AI tradeThe divergent market reactions suggest investors are becoming more selective about AI spending. Companies may still be able to commit billions of dollars to infrastructure, but the market increasingly wants evidence that this spending can support revenue and cash-flow growth.

Wood said results announced so far have not signalled a decline in hyperscaler capex, which is why analysts have yet to cut earnings forecasts for companies such as memory chip producers. But the negative response to higher spending represents an important shift in market behaviour.

The continuing unwind in semiconductor stocks has already pushed some companies close to their 200-day moving averages. Wood said the correction could be limited if it merely represents a technical flushing out of leveraged positions accumulated by momentum traders. The bigger risk is that the violent selloff is anticipating an eventual slowdown in hyperscaler spending.

Korea’s AI trade suffers a brutal reversal

The scale of the speculative unwind is particularly evident in South Korea, one of the biggest beneficiaries of the global semiconductor rally.

The Kospi has fallen 40% from its all-time high of 9,385.6 reached on June 19. Foreign investors have sold a net $116 billion of Korean equities so far this year across the cash and futures markets, with technology stocks accounting for $104 billion of that selling.

Assets in domestic leveraged exchange-traded funds tracking Korean equities have collapsed to $17 billion, down 66% from their $50 billion peak on June 22. However, retail margin-loan balances remain elevated at $22.8 billion, only $2.4 billion below their peak in late May.

Dedicated domestic ETFs tracking Korean equities have received net creations of $48 billion this year, providing some counterweight to the foreign exodus.

Korea’s neutral weighting in the MSCI AC Asia Pacific ex-Japan Index has meanwhile fallen to 17.5% from a peak of 24.6% in late June. The sharp decline highlights how rapidly index exposure and foreign positioning can reverse when investors begin questioning the assumptions underpinning a crowded trade.

Wood sees China emerging as the AI winner

Wood continues to believe that China is best positioned to prevail in AI, particularly in the mass consumer market. His thesis does not assume that demand for computing power will collapse. Instead, he expects demand to keep expanding even if the customers and eventual winners change.

That distinction is central to his outlook that AI may continue transforming the economy while still delivering disappointing financial returns for companies funding the infrastructure buildout.

China’s rapidly growing semiconductor industry also provides a striking counterpoint to the selloff elsewhere. CXMT, the country’s leading DRAM manufacturer, surged 500% after listing. Its market capitalisation reached $523 billion, briefly making it the most valuable company listed in mainland China.

CXMT’s valuation exceeded Industrial and Commercial Bank of China’s $410 billion market capitalisation and was just below Hong Kong-listed Tencent’s $547 billion.

The extraordinary debut came during a week in which global memory stocks remained under intense pressure, demonstrating that investor appetite for AI has not disappeared. Instead, capital may be rotating towards companies offering lower starting valuations or greater exposure to China’s domestic technology ecosystem.

The critical question is no longer whether AI demand will grow, but who will capture the economics of that growth. Wood’s warning is that the companies spending the most may not necessarily emerge as the biggest winners and the market has started demanding proof before financing the next phase of the capex boom.

This article was written by

Analyst’s Disclosure: I/we have a beneficial long position in the shares of FTHNX either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

This article was written by

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Pharma player Divi’s Laboratories on Saturday reported a consolidated net profit of Rs 902 crore for the April-June quarter of FY26, marking a 65.5% year-on-year rise from the Rs 545 crore reported in the corresponding quarter of the previous financial year.

The firm’s revenue from operations meanwhile rose around 28% YoY to Rs 3,080 crore in Q1 FY27, from Rs 2,410 crore reported in the year-ago period. Its total income increased over 24% YoY to Rs 3,144 crore, while total expenses rose more than 9% YoY to Rs 1,964 crore during the quarter which ended on June 30, 2026.

For the quarter, Divi’s Labs reported a forex loss of Rs 7 crore as against a forex gain of Rs 39 crore for the corresponding quarter of the previous financial year. Profit before tax (PBT) for the quarter rose to Rs 1,180 crore, as against a PBT of Rs 733 crores for the corresponding quarter of the previous financial year.

Along with the Q1 earnings, Divi’s Labs said that its board of directors have approved the appointment of B Vara Prasad and J Srinivasa Rao as senior management personnel of the company, with effect from August 1.

Also read | ITC Q1 profit plunges 27% due to record cigarette taxes and West Asia crisis

Divi’s Labs share price

Divi’s Labs shares gained nearly 3% to close at Rs 8,056 apiece on Friday, before the quarterly earnings were announced on Saturday. The stock has gained over 11.5% in one week and 23% in a month.

The shares of the company have overall jumped more than 27% in 2026 so far. In the longer term, the stock has delivered 23% returns over one year, 119% in three years and 65% in five years. The company’s market capitalisation stands at nearly Rs 2.15 lakh crore.
Also read | Bajaj Finserv Q1 Results: Net profit rises 12% YoY to Rs 3,132 crore; shares rally 5%
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)

Follow